In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • Survivin Gene Polymorphism and Serum Survivin Levels in Patients with Brain Tumors

    Final Number:
    1706

    Authors:
    Didem Kafadar; Ilhan Yaylim BS, PhD; Ali Metin Kafadar As.Prof. MD.; Canan Cacina; Arzu Ergen; Mehmet Yasar Kaynar MD; Turgay Isbir

    Study Design:
    Laboratory Investigation

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2013 Annual Meeting

    Introduction: Survivin, has a key role in in the regulation of apoptosis and cell division, is one of the apoptosis inhibitor family(IAP) proteins. A single nucleotide polymorphism -31C/G was identified in the promoter region of the survivin gene seemed to be associated with over-expression of survivin protein and changed transcription in various cancer cell lines. Our aim was to investigate whether survivin gene polymorphism can be accepted as a marker of tumor risk and progression in patients with benign and malign brain tumors and if the polymorphism affects survivin serum levels.

    Methods: Survivin promoter -31C/G polymorphism was genotyped by a polymerase chain recation-restriction fragment length polymorphism (PCR-RFLP) assay analysis in 82 patients with intracranial primary tumors and 65 healthy controls.

    Results: There were no differences in the distribution of survivin promotor -31C>G genotypes and alleles between patients with primary brain tumours and controls. Serum survivin levels in patients with malign tumors were significantly higher than those in patients with benign tumors (p<0.001) and survivin levels in patients with malign glial tumors who have survivin promotor -31GG genotype were significantly higher than those in controls ( p=0.05) and benign tumors (p=0.04).Patients with malign nonglial tumors carrying C allele were significantly higher than the control group.C allele frequency of the -31C/G gene polymorphism in patients with meningeal tumors diagnosed younger than 45 years was significantly higher than patients over 45. In GBM patients under 45, GG genotype was significantly higher than patients over 45.

    Conclusions: We suggest that survivin Promotor -31C>G polymorphism may be as a marker of tumour risk and progression in primary brain tumors. C allele frequency is found significantly higher in various cancers in certain studies.According to our results C allele may be associated with malign nonglial tumors and young onset of meningeal origin tumors.Being under 45 at diagnosis is reported to be associated with prognosis. G allele may be associated with young onset of malign glial tumors. The patients should be followed for more precise results about prognosis and genotype relationship and the study must be verified in larger patient groups.

    Patient Care: These findings if confirmed in larger patient groups may have clinical value in assessment of the genetic risk and tumour progression in brain tumors thus opening new perspectives for the study of molecular factors underlying the mechanisms of primary brain tumors.

    Learning Objectives: 1)Describe the importance of survivin polymorphism. 2) Discuss serum levels and polymorphism of survivin in benign and malign brain tumors.3) Discuss whether survivin may be a tumor therapy target.

    References:

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy